About the Company and its Mission:

ProMIS™ Neurosciences, Inc., headquartered in Toronto Ontario, and with offices in Cambridge Massachusetts, is publicly traded on the TSX (ticker symbol: PMN.TO). As a development stage biotech company ProMIS’ mission is the discovery and development of best in class precision therapeutics for treatment of neurodegenerative diseases, in particular Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS).

Precision Medicine – targeting the right drug to the right patient by using both a diagnostic and a therapeutic together – has had dramatic positive impact in a number of diseases. It appears to be important in Alzheimer’s and neurodegenerative disease as well.
As its primary objective, the Company will focus on the discovery and development of
precision therapeutics directed against several strains of misfolded, neurotoxic prion forms of Amyloid beta (Aβ), the root cause of Alzheimer’s.

The Company’s scientific foundation is centered on the growing consensus that prion forms of misfolded proteins are key drivers of neurodegenerative diseases. Prion forms of misfolded proteins are characterized by their neurotoxicity and ability to progressively spread throughout the brain, killing neurons. Numerous neurodegenerative diseases exhibit toxic, prion-like protein misfolding, in particular Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). Recent published evidence indicates that for a given misfolded protein there exist multiple prion-like strains, each strain representing a target against which specific therapeutics can be developed. ProMIS has identified distinct targets on strains of misfolded SOD1 in ALS and on misfolded strains of Amyloid beta in AD.

Core Science & Technology. The company is based around the leading science of Dr. Neil Cashman, Professor of Medicine at the University of British Columbia, Neuroscientist at the Brain Research Center, and Academic Director of the Vancouver Coastal Hospital ALS Center. For over two decades, Neil Cashman has been among the leaders in the field of misfolded proteins (with over 300 publications and over 10,000 citations and 45 patent applications), and is one of several leading researchers of strain specific protein misfolding.

Intellectual Property.
Based primarily on the research of ProMIS CSO, Dr. Neil Cashman, the Company has exclusive access to critical IP and proprietary know-how in the field. In addition, based on work from both Cashman’s lab, and ProMIS Chief Physics Officer, Steven Plotkin, ProMIS Neurosciences, Inc. utilizes two proprietary computational discovery technologies, ProMIS™ and Collective Coordinates, to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. ProMIS™ Neurosciences has a broad patent estate granted relating to misfolded SOD1 in ALS and multiple patents submitted for disease specific epitopes (targets) on misfolded Amyloid beta in AD.

Harnessing the power of precision medicine to conquer Alzheimer’s disease.

Harnessing the power of precision medicine to treat Alzheimers and ALS. This is a video update on exciting progress with precision medicine therapies for Alzheimer’s.